[AF] Comer sin calorias

Hugo Guedes de Souza hugo en imafar.com.br
Mar Oct 5 16:19:09 CEST 2004

Segue anexado trabalhado clinico publicado no PUBMED sobre a extrato de
Phaseolus vulgaris
hugo en imafar.com.br

Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Profile Links HomoloGene Links Nucleotide Links OMIM Links PubChem BioAssay PC Compound Links PC Compound via MeSH PC Substance Links PC Substance via MeSH PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links  Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order

1: Altern Med Rev. 2004 Mar;9(1):63-9.
Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract.

Udani J, Hardy M, Madsen DC.

UCLA School of Medicine, Integrative Medicine Program, Northridge Hospital, 8250 Roscoe Blvd, Suite 240, Northridge, CA 91325, USA. Jay.Udani en CHW.edu

Background: Phase 2' starch neutralizer brand bean extract product ("Phase 2") is a water-extract of a common white bean (Phaseolus vulgaris) that has been shown in vitro to inhibit the digestive enzyme alpha-amylase. Inhibiting this enzyme may prevent the digestion of complex carbohydrates, thus decreasing the number of carbohydrate calories absorbed and potentially promoting weight loss. Methods: Fifty obese adults were screened to participate in a randomized, double-blind, placebo-controlled study evaluating the effects of treatment with Phase 2 versus placebo on weight loss. Participants were randomized to receive either 1500 mg Phase 2 or an identical placebo twice daily with meals. The active study period was eight weeks. Thirty-nine subjects completed the initial screening process and 27 subjects completed the study. Results: The results after eight weeks demonstrated the Phase 2 group lost an average of 3.79 lbs (average of 0.47 lb per week) compared with the placebo group, which lost an average of 1.65 lbs (average of 0.21 lb per week), representing a difference of 129 percent (p=0.35). Triglyceride levels in the Phase 2 group were reduced an average of 26.3 mg/dL, more than three times greater a reduction than observed in the placebo group (8.2 mg/dL) (p=0.07). No adverse events during the study were attributed to the study medication. Conclusion: Clinical trends were identified for weight loss and a decrease in triglycerides, although statistical significance was not reached. Phase 2 shows potential promise as an adjunct therapy in the treatment of obesity and hypertriglyceridemia and further studies with larger numbers of subjects are warranted to conclusively demonstrate effectiveness.

Publication Types: 
Clinical Trial 
Randomized Controlled Trial 

PMID: 15005645 [PubMed - indexed for MEDLINE] 

Más información sobre la lista de distribución AF